Exp Clin Endocrinol Diabetes 2024; 132(08): 469-475
DOI: 10.1055/a-2322-7355
Article

Demonstration of Epstein-Barr Virus by In Situ Hybridization in Papillary Thyroid Carcinomas Developing on Background of Hashimoto’s Thyroiditis

Serap Karaarslan
1   Department of Pathology, İzmir Tınaztepe University, İzmir, Turkey
,
Esin Kasap
2   Department of Obstetrics and Gynecology, University of Health Sciences Tepecik Education and Research Hospital, İzmir, Turkey
,
Fatma Nur İpek
3   Private Ege Pathology Laboratory, İzmir, Turkey
,
Mahir Akyıldız
4   Department of General Surgery, Ege University, İzmir Turkey
› Author Affiliations

Abstract

Aim This study aimed to demonstrate the role of Epstein-Barr Virus (EBV) in papillary thyroid carcinomas (PTC) developing on the background of Hashimotoʼs thyroiditis (HT).

Methods The presence of EBV in tumoral tissue, lymphocytes, and peritumoral normal thyroid tissue was investigated using the in situ hybridization method in paraffin blocks. The subtypes of PTC, tumor diameter, TNM stage, multifocality, invasion of thyroid capsule, perineural invasion, and muscular tissue invasion were identified and compared according to EBV involvement.

Results Eighty-one patients with HT diagnosis, with 93.8% (n=76) female and 6.2% (n=5) male, were included in the study. Papillary microcarcinoma was the pathological diagnosis in 24.2% (n=15) of the cases. EBV was identified in 58.06% (n=36) of the tumor cells nuclei, 58.06% (n=36) in the tumor cell cytoplasm, 16.12% (n=10) in tumor infiltrative lymphocytes, and 53.2% (n=33) in normal parenchymal follicle epithelial cells (NPFEC). In the T2 stage, the rate of EBV nuclear positivity in patients was significantly higher (p=0.034). The classic variant of papillary carcinoma was accompanied by a significantly higher rate of EBV-negative NPFEC (67.6%, p=0.049). In multifocal tumors, EBV positivity was found to be significantly higher in lymphocytes in the surrounding tissues (58.3%, p=0.034).

Conclusion A significant increase in EBV positivity in the surrounding tissue lymphocytes was observed in multifocal PTC developing on a background of HT. This suggests a possible association between HT and EBV.



Publication History

Received: 28 January 2024
Received: 04 April 2024

Accepted: 30 April 2024

Accepted Manuscript online:
08 May 2024

Article published online:
03 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Kieff E, Rickinson AB. Epstein–Barr Virus and its Replication. In: DM Knipe, PM Howley, eds. Fields Virology. Philadelphia: Lippincott; Williams, and Wilkins; 2007: 2603-2654
  • 2 Thomas D, Karachaliou F, Kallergi K. et al. Herpes virus antibodies seroprevalence in children with autoimmune thyroid disease. Endocrine 2008; 33: 171-175
  • 3 Young LS, Rickinson AB. Epstein-Barr virus: 40 Years on. Nat Rev Cancer 2004; 4: 757-768
  • 4 Kannangai R, Sachithanandham J, Kandathil AJ. et al. Immune responses to Epstein-Barr virus in individuals with systemic and organ specific autoimmune disorders. Indian J Med Microbiol 2010; 28: 120-123
  • 5 Niller HH, Salamon D, Ilg K. et al. EBV-associated neoplasms: Alternative pathogenetic pathways. Med Hypotheses 2004; 62: 387-391
  • 6 Kanda T, Yajima M, Ikuta K. Epstein-Barr virus strain variation and cancer. Cancer Sci 2019; 110: 1132-1139
  • 7 Young LS, Murray PG. Epstein-Barr virus and oncogenesis: From latent genes to tumours. Oncogene 2003; 11: 5108-5121
  • 8 Taylor GS, Long HM, Brooks JM. et al The immunology of epstein-barr virus-induced disease. Annu Rev Immunol 2015; 33: 787-821
  • 9 Arai A. Chronic active Epstein–Barr virus infection: A bi-faceted disease with inflammatory and neoplastic elements. Immunol Med 2018; 41: 162-169
  • 10 Desailloud R, Hober D. Viruses and thyroiditis: An update. Virol J 2009; 6: 5
  • 11 Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune diseases. Front Immunol 2021; 11: 587380
  • 12 Chen YK, Lin CL, Cheng FTF. et al. Cancer risk in patients with Hashimoto’s thyroiditis: A nationwide cohort study. Br J Cancer 2013; 109: 2496-2501
  • 13 Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol 2002; 10: 141-146
  • 14 Schäffler A, Palitzsch KD, Seiffarth C. et al. Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur J Clin Invest 1998; 28: 838-844
  • 15 Leoncini E, Ricciardi W, Cadoni G. et al. Adult height and head and neck cancer: A pooled analysis within the INHANCE Consortium. Head Neck 2014; 36: 1391
  • 16 Hanege FM, Tuysuz O, Celik S. et al. Hashimoto’s thyroiditis in papillary thyroid carcinoma: A 22-year study. Acta Otorhinolaryngol Ital 2021; 41: 142-145
  • 17 Konturek A, Barczyński M, Nowak W. et al. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto’s thyroiditis. Langenbeck’s Arch Surg 2014; 399: 229-236
  • 18 Noureldine SI, Tufano RP. Association of Hashimoto’s thyroiditis and thyroid cancer. Curr Opin Oncol 2015; 27: 21-25
  • 19 Stamatiou D, Derdas SP, Symvoulakis EK. et al. Investigation of BK virus, Epstein-Barr virus and human papillomavirus sequences in postoperative thyroid gland specimens. Int J Biol Markers 2015; 30: e104-e110
  • 20 Stamatiou DP, Derdas SP, Zoras OL. et al. Herpes and polyoma family viruses in thyroid cancer. Oncol Lett 2016; 11: 1635-1644
  • 21 Shukla SK, Singh G, Ahmad S. et al Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases. Microb Pathog 2018; 116: 279-288
  • 22 Almeida JFM, Campos AH, Marcello MA. et al. Investigation on the association between thyroid tumorigeneses and herpesviruses. J Endocrinol Invest 2017; 40: 823-829
  • 23 Cunha LL, Ward LS. Concurrent lymphocytic thyroiditis is associated to less aggressive papillary thyroid carcinomas. Eur Arch Oto-Rhino-Laryngology 2012; 269: 699-700
  • 24 de Almeida JFM, Ward LS. Thyroid autoimmune diseases and thyroid tumors: Would EBV infection be the link?. J Cell Physiol 2019; 234: 19141-19142
  • 25 Liu J, Kong X, Huang T. et al. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: A pan-cancer study. Front Immunol 2020; 11: 2048
  • 26 Almeida JFM, Proenca-Modena JL, Bufalo NE. et al. Epstein–Barr virus induces morphological and molecular changes in thyroid neoplastic cells. Endocrine 2020; 69: 321-330
  • 27 Golden S. The Epstein-Barr virus EBNA2 protein induces a subset of NOTCH target genes in thyroid cancer cell lines but fails to suppress proliferation. Physiol Behav 2018; 176: 139-148
  • 28 Pani F, Caria P, Yasuda Y. et al. The immune landscape of papillary thyroid cancer in the context of autoimmune thyroiditis. Cancers (Basel) 2022; 14: 4287
  • 29 Chui MH, Cassol CA, Asa SL. et al. Follicular epithelial of the thyroid: Morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymhocytic thyroiditid. Virchows Arch 2013; 462: 557-563
  • 30 Bychkov A, Keelawat S. Epstein–Barr virus and thyroid cancer: The controversy remains. J Endocrinol Invest 2017; 40: 891-892
  • 31 Homayouni M, Mohammad Arabzadeh SA, Nili F. et al. Evaluation of the presence of Epstein-Barr virus (EBV) in Iranian patients with thyroid papillary carcinoma. Pathol Res Prac 2017; 213: 854-856